Emergent BioSolutions
EBS · NYSE · United States
Share price · EBS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when EBS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-5.6%
- 5 Oct 2026+14.4%
Nothing announced by EBS that day or the session before.
- 7 Aug 2026-8.9%
Nothing announced by EBS that day or the session before.
- 6 Aug 2026-29.6%
- 14 Jul 2026-6.4%
Nothing announced by EBS that day or the session before.
- 25 Jun 2026-5.3%
Nothing announced by EBS that day or the session before.
- 2 Mar 2026+10.3%
Nothing announced by EBS that day or the session before.
- 27 Feb 2026-26.6%
Share of unusual movement by asset
For each asset, the share of EBS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Naloxone (Narcan) (Narcan)events and moves
| 1 | shown from 8 days |
ACAM2000events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 47% |
| Sessions with no dated event | — | 53% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Orthopoxvirus immunity (live vaccinia vaccine)Vaccine | Poxvirus Infections Smallpox and Mpox | |
| Approved | B. anthracis protective antigenVaccine | Anthrax | |
| Approved | Opioid receptorSmall molecule | Opioid Overdose |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $110M | $9.4M | $177M | $33M$100M operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $9.2M | $141M | $180M$56M operating cash flow | report ↗ |
| 2026-Q1 | — | $11M | $162M | —-$34M operating cash flow | report ↗ |
| 2025-Q3 | — | $14M | $249M | —-$2.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $13M | $271M | $12M$106M operating cash flow | report ↗ |
| 2025-Q1 | — | $15M | $153M | —-$11M operating cash flow | report ↗ |
| 2024-Q3 | $294M | $14M | $156M | —$154M operating cash flow | report ↗ |
| 2024-Q2 | $255M | $33M | $71M | $283M$48M operating cash flow | report ↗ |
| 2024-Q1 | $300M | $15M | $79M | —-$63M operating cash flow | report ↗ |
| 2023-Q3 | $271M | $15M | $88M | $263M$60M operating cash flow | report ↗ |
| 2023-Q2 | $338M | $26M | $89M | $261M-$114M operating cash flow | report ↗ |
| 2023-Q1 | $165M | $41M | $430M | $183M-$184M operating cash flow | report ↗ |
| 2022-Q4 | $330M | — | $643M | $67M$93M operating cash flow | report ↗ |
| 2022-Q3 | $240M | $39M | $241M | $76M-$74M operating cash flow | report ↗ |
| 2022-Q2 | $243M | $50M | $358M | $56M-$16M operating cash flow | report ↗ |
| 2022-Q1 | $308M | $46M | $436M | $3.7M-$37M operating cash flow | report ↗ |
| 2021-Q4 | $733M | — | $576M | —$329M operating cash flow | report ↗ |
| 2021-Q3 | $329M | $50M | $404M | $33M$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $743M | $53M | $209M | —$171M operating cash flow | report ↗ |
For fiscal 2025, Emergent BioSolutions reported revenue of $742.9M, down 28.8% YoY from $1,043.6M, with R&D spend of $53.2M, down 24.8% YoY. Cash and equivalents totaled $209.1M, and the company reported net income of $52.6M; quarterly net burn was not disclosed.
During the year, management highlighted completion of the Baltimore-Bayview facility sale to Syngene for approximately $36.5M, acquisition of exclusive U.S. and Canadian commercial rights to KLOXXADO from Hikma, and receipt of all $80.0M in Bavarian Nordic milestones. The company also secured multiple U.S. government contract actions across ACAM2000, CYFENDUS, CNJ-016, BAT, TEMBEXA, and BioThrax, plus a BARDA option for Ebanga, while deciding at year-end to deprioritize several early-stage candidates, including EBS-MARV, EBS-SUDV, Pan-Ebola mAbs, and WEVEE-VLP.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($986K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-07 | DeGolyer Donald W · director | Open-market sale | 17,800 | $7.09 | $126K | Form 4 |
| 2026-10-01 | Williams Paul Anthony · SVP, Products Business | Open-market sale | 3,000 | $6.53 | $20K | Form 4 |
| 2026-07-01 | Williams Paul Anthony · SVP, Products Business | Open-market sale | 3,000 | $8.40 | $25K | Form 4 |
| 2026-06-08 | Hartzel William · SVP, Bioservices | Tax withholding | 1,741 | $8.00 | $14K | Form 4 |
| 2026-06-08 | Glessner Coleen · EVP, Quality & Ethics, and CPL | Tax withholding | 2,018 | $8.00 | $16K | Form 4 |
| 2026-06-08 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Tax withholding | 3,964 | $8.00 | $32K | Form 4 |
| 2026-06-08 | Williams Paul Anthony · SVP, Products Business | Tax withholding | 694 | $8.00 | $6K | Form 4 |
| 2026-05-01 | Zoon Kathryn C · director | Open-market sale | 16,145 | $8.36 | $135K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 187 reporting institutions held 42.6M shares ($331.8M, 82.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 4,341,462 | $36.0M |
| 2 | STATE STREET CORP | 2,849,701 | $23.7M |
| 3 | DIMENSIONAL FUND ADVISORS LP | 2,757,158 | $22.9M |
| 4 | AMERICAN CENTURY COMPANIES INC | 2,425,722 | $20.1M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,257,995 | $18.7M |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,506,075 | $12.5M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1,272,909 | $10.6M |
| 8 | PALISADE CAPITAL MANAGEMENT, LP | 1,201,323 | $10.0M |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,117,278 | $9.3M |
| 10 | OAK HILL ADVISORS LP | 1,113,338 | $9.2M |
| 11 | D. E. Shaw & Co., Inc. | 1,003,912 | $8.3M |
| 12 | AQR CAPITAL MANAGEMENT LLC | 989,677 | $8.2M |
| 13 | GOLDMAN SACHS GROUP INC | 811,560 | $6.7M |
| 14 | Prescott Group Capital Management, L.L.C. | 772,771 | $6.4M |
| 15 | MORGAN STANLEY | 744,536 | $6.2M |